Liu, Chun
(2024)
Characterizing “Exposure-PK/PD-Biomarker” relationships in patients with hematologic malignancies, [Dissertation thesis], Alma Mater Studiorum Università di Bologna.
Dottorato di ricerca in
Scienze mediche generali e scienze dei servizi, 36 Ciclo.
Documenti full-text disponibili:
![[img]](http://amsdottorato.unibo.it/style/images/fileicons/application_pdf.png) |
Documento PDF (English)
- Accesso riservato fino a 1 Gennaio 2025
- Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Salvo eventuali più ampie autorizzazioni dell'autore, la tesi può essere liberamente consultata e può essere effettuato il salvataggio e la stampa di una copia per fini strettamente personali di studio, di ricerca e di insegnamento, con espresso divieto di qualunque utilizzo direttamente o indirettamente commerciale. Ogni altro diritto sul materiale è riservato.
Download (11MB)
| Contatta l'autore
|
Abstract
Antimicrobial stewardship programs are gaining more and more relevance in optimizing anti-infective treatment and in preventing the emergence of antimicrobial resistance. Personalization of antimicrobial treatment based on real-time therapeutic drug morning (TDM) and dosing adaptation may represent an important tool in antimicrobial stewardship programs.
In this Ph.D project, we aim to focus on differences in pharmacokinetics (PK) for meropenem and piperacillin/tazobactam and host response biomarkers (e.g., C-reactive protein) in severe Gram‐negative related infections occurring in oncohematologic patients. We are interested in identifying optimized model‐based individualized dosing strategies for these antibiotics focusing on biomarkers-guided prediction of PK and pharmacodynamic (PD) parameters using population PK/PD modelling. We expect to identify optimal model‐based dosing targets for these antibiotics for special populations for implementation in TDM routines, and mathematical models characterizing the relationship between biomarkers and outcomes in these populations.
Abstract
Antimicrobial stewardship programs are gaining more and more relevance in optimizing anti-infective treatment and in preventing the emergence of antimicrobial resistance. Personalization of antimicrobial treatment based on real-time therapeutic drug morning (TDM) and dosing adaptation may represent an important tool in antimicrobial stewardship programs.
In this Ph.D project, we aim to focus on differences in pharmacokinetics (PK) for meropenem and piperacillin/tazobactam and host response biomarkers (e.g., C-reactive protein) in severe Gram‐negative related infections occurring in oncohematologic patients. We are interested in identifying optimized model‐based individualized dosing strategies for these antibiotics focusing on biomarkers-guided prediction of PK and pharmacodynamic (PD) parameters using population PK/PD modelling. We expect to identify optimal model‐based dosing targets for these antibiotics for special populations for implementation in TDM routines, and mathematical models characterizing the relationship between biomarkers and outcomes in these populations.
Tipologia del documento
Tesi di dottorato
Autore
Liu, Chun
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
36
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
PK/PD modeling, antibiotic, biomarker, hematologic malignancies, therapeutic drug monitoring.
URN:NBN
Data di discussione
5 Aprile 2024
URI
Altri metadati
Tipologia del documento
Tesi di dottorato
Autore
Liu, Chun
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
36
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
PK/PD modeling, antibiotic, biomarker, hematologic malignancies, therapeutic drug monitoring.
URN:NBN
Data di discussione
5 Aprile 2024
URI
Gestione del documento: